Nearly Half of U.S. COVID-19 Cases Now Caused by JN.1 Variant
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Dec. 28, 2023 -- The JN.1 variant, a descendant of the variant BA.2.86, now accounts for 44 percent of COVID-19 cases, up from roughly 7 percent in late November, the latest data from the U.S. Centers for Disease Control and Prevention show.
The speed at which the JN.1 variant has spread this month suggests it may spread more easily and be better at evading immune systems than other circulating variants, according to a recent CDC report. "It is too early to know whether or to what extent JN.1 will cause an increase in infections or hospitalizations," the CDC said in its report.
Luckily, JN.1 does not seem to be causing more severe illness yet. Additionally, the updated COVID-19 vaccines that were released in September produce antibodies that work against JN.1, which is distantly related to the XBB.1.5 variant the tweaked vaccines target.
Despite the fact that JN.1 may not cause more severe disease than other variants, hospitalizations have started creeping up recently. For the week of Dec. 10, there were just under 26,000 COVID-19-linked hospitalizations, a 10 percent increase from about 23,000 hospitalizations the week before. However, those numbers are still far lower than they were during the peak of the tripledemic last winter, when COVID-19, flu, and respiratory syncytial virus cases all surged simultaneously.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Further Support and Information on COVID-19
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
Elevated BMI Linked to Postacute Sequelae of SARS-CoV-2 in Children
WEDNESDAY, Oct. 30, 2024 -- For children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, elevated body mass index (BMI) is associated with an...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.